Literature DB >> 9027954

Liver transplantation in Europe for patients with acute liver failure.

H Bismuth1, D Samuel, D Castaing, R Williams, S P Pereira.   

Abstract

Approximately 11% of all liver transplants performed in Europe are for acute liver failure, with one-year patient survival rates ranging between 50% and 75%. This review summarizes the selection, perioperative management, and outcome of patients transplanted for acute liver failure, with particular reference to the experience at the Hôpital Paul Brousse in Paris and at King's College Hospital, London. In both centers, the decision to proceed to liver transplantation is based on criteria that predict a survival of less than 20% with medical management alone. Infectious complications and cerebral edema remain the most common causes of death, and highlight the importance of intensive monitoring and early treatment of perioperative complications. In selected patients, auxiliary partial orthotopic liver transplantation may be a therapeutic option, with the potential for native liver generation and eventual immunosuppression withdrawal in approximately two-thirds of patients.

Entities:  

Mesh:

Year:  1996        PMID: 9027954     DOI: 10.1055/s-2007-1007254

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  23 in total

Review 1.  Treatment of acute liver failure.

Authors:  K H Boeker
Journal:  Metab Brain Dis       Date:  2001-06       Impact factor: 3.584

Review 2.  Therapeutic application of stem cells in gastroenterology: an up-date.

Authors:  Patrizia Burra; Debora Bizzaro; Rachele Ciccocioppo; Fabio Marra; Anna Chiara Piscaglia; Laura Porretti; Antonio Gasbarrini; Francesco Paolo Russo
Journal:  World J Gastroenterol       Date:  2011-09-14       Impact factor: 5.742

3.  Brain aquaporin-4 in experimental acute liver failure.

Authors:  Kakulavarapu V Rama Rao; Arumugam R Jayakumar; Xiaoying Tong; Kevin M Curtis; Michael D Norenberg
Journal:  J Neuropathol Exp Neurol       Date:  2010-09       Impact factor: 3.685

4.  Molecular adsorbent recirculating system dialysis in patients with acute liver failure who are assessed for liver transplantation.

Authors:  Christophe Camus; Sylvain Lavoué; Arnaud Gacouin; Yves Le Tulzo; Richard Lorho; Karim Boudjéma; Christian Jacquelinet; Rémi Thomas
Journal:  Intensive Care Med       Date:  2006-08-29       Impact factor: 17.440

Review 5.  Therapy of intracranial hypertension in patients with fulminant hepatic failure.

Authors:  Murugan Raghavan; Paul E Marik
Journal:  Neurocrit Care       Date:  2006       Impact factor: 3.210

Review 6.  Signaling factors in the mechanism of ammonia neurotoxicity.

Authors:  M D Norenberg; K V Rama Rao; A R Jayakumar
Journal:  Metab Brain Dis       Date:  2008-12-23       Impact factor: 3.584

7.  NFkappaB in the mechanism of ammonia-induced astrocyte swelling in culture.

Authors:  Anne P Sinke; Arumugam R Jayakumar; Kiran S Panickar; Mitsuaki Moriyama; Pichili V B Reddy; Michael D Norenberg
Journal:  J Neurochem       Date:  2008-07-04       Impact factor: 5.372

Review 8.  New concepts in the mechanism of ammonia-induced astrocyte swelling.

Authors:  M D Norenberg; A R Jayakumar; K V Rama Rao; K S Panickar
Journal:  Metab Brain Dis       Date:  2007-12       Impact factor: 3.584

9.  Marked potentiation of cell swelling by cytokines in ammonia-sensitized cultured astrocytes.

Authors:  Kakulavarapu V Rama Rao; Arumugam R Jayakumar; Xiaoying Tong; Veronica M Alvarez; Michael D Norenberg
Journal:  J Neuroinflammation       Date:  2010-10-13       Impact factor: 8.322

10.  Liver transplantation for fulminant hepatic failure: experience with more than 200 patients over a 17-year period.

Authors:  Douglas G Farmer; Dean M Anselmo; R Mark Ghobrial; Hasan Yersiz; Suzanne V McDiarmid; Carlos Cao; Michael Weaver; Jesus Figueroa; Khurram Khan; Jorge Vargas; Sammy Saab; Steven Han; Francisco Durazo; Leonard Goldstein; Curtis Holt; Ronald W Busuttil
Journal:  Ann Surg       Date:  2003-05       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.